Glaukos Reports 2017 Net Sales of $159.3 Million

March 9, 2018: By Joan McKenna

Glaukos reported Feb. 28 that 2017 net sales of its iStent implant totaled $159.3 million, a 39 percent increase over 2016 sales of $114.4 million.

Glaukos’ Q4-2017 net sales totaled $41.7 million, an increase of 26 percent year over year.

The San Clemente, California, company attributed the growth to unit volume increases worldwide, higher average selling prices, and expansion of the company’s direct sales operations to new international markets.

Glaukos launched the iStent, the first minimally invasive glaucoma surgery (MIGS) device, in 2012.

The device now faces growing competition, with other MIGS stents commercialized in late 2016 and 2017.

Glaukos provided net sales guidance for 2018 of $160 million to $165 million, the same range the firm initially provided for 2017.

In May 2017, Glaukos’ full-year guidance for 2017 was raised to $162 million to $167 million. In September 2017, the company lowered it to $155 million to $160 million.

Glaukos’ net loss in 2017 was $0.1 million compared with net income of $4.5 million in 2016.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales